RAPT Therapeutics
SOUTH SAN FRANCISCO, CA, United States · Biotechnology · 141 employees
Rapt Therapeutics is a pharmaceutical firm developing novel therapies for patients living with inflammatory and immunologic diseases. The company focuses on creating innovative treatments for serious health conditions, particularly in the field of food allergies.
Funding history
- Funding Round — $250.0M — Oct 2025
- Funding Round — $150.0M — Jan 2025
- Funding Round — $50.0M — Jun 2022
- Funding Round — $37.1M — Jun 2019
- Funding Round — $22.6M — Jan 2019
Recent signals
- Oct 22, 2025: Raised $250.0M
- Oct 21, 2025: SEC 8-K (1.01): On October 21, 2025, RAPT Therapeutics, Inc. entered into an Underwriting Agreement with a consortium of underwriters, including Leerink Partners LLC and Wells Fargo Securities, among others, for a public offering of 8,333,334 shares of its common stock. The shares are being offered to the public at a price of $30.00 each, while the company will receive $28.20 per share, raising significant funds for its operations. An option was granted to underwriters to purchase additional shares under certain conditions. The strategic implications of this offering could enhance the company's financial position and support its developmental goals.
- Jan 03, 2025: Raised $150.0M
- Dec 23, 2024: RAPT Therapeutics Partners with Jemincare and Secures Funding
- Dec 23, 2024: RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody
- Feb 13, 2024: RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations
- Jun 03, 2022: Raised $50.0M
- Jun 20, 2019: Raised $37.1M
See plans & pricing → Track RAPT Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.